ITGB1 and androgen insensitivity syndrome: Abciximab, a chimeric monoclonal antibody targeting glycoprotein IIa/IIIb receptor, has also been used to treat AIS patients; unfortunately, abciximab significantly increased the risk of intracranial hemorrhage (32).